Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. LSTA
LSTA logo

LSTA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Lisata Therapeutics Inc (LSTA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
5.030
1 Day change
52 Week Range
5.070
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Lisata Therapeutics Inc (LSTA) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of significant trading trends, neutral insider and hedge fund sentiment, poor financial performance, and absence of positive news or catalysts make it a stock to hold off on for now.

Technical Analysis

The MACD histogram is negative (-0.101) and contracting, indicating bearish momentum. RSI is neutral at 37.155, and moving averages are converging, showing no clear trend. Key support is at 4.109, and resistance is at 4.498. The stock has an 80% chance to increase 0.06% in the next day and 10.81% in the next month, but these are not compelling enough for a buy signal.

Positive Catalysts

  • NULL. No recent news or significant trading trends. Gross margin remains at 100%, but this is offset by poor overall financial performance.

Neutral/Negative Catalysts

  • No significant insider or hedge fund activity. Lack of valuation data and no recent congress trading activity.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped to -$4,249,000 (-13.81% YoY), and EPS fell to -0.49 (-16.95% YoY). Gross margin remained at 100%, but this does not offset the negative income and EPS trends.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available for this stock.

Wall Street analysts forecast LSTA stock price to rise
Analyst Rating
0
Wall Street analysts forecast LSTA stock price to rise
Buy
Hold
Sell
0
Current: 5.030
sliders
Low
0
Averages
0
High
0
0
Current: 5.030
sliders
Low
0
Averages
0
High
0
Brookline
Buy
maintain
$20 -> $32
AI Analysis
2025-07-15
Reason
Brookline
Price Target
$20 -> $32
AI Analysis
2025-07-15
maintain
Buy
Reason
Brookline raised the firm's price target on Lisata Therapeutics to $32 from $20 and keeps a Buy rating on the shares. The firm cites extended patent protection for the target increase after Lisata received a new patent for certepetide through March 2040.

People Also Watch